Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 30 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | March 2014 |
| End Date: | August 2014 |
A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease
The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease
subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will
also be evaluated.
subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will
also be evaluated.
Inclusion Criteria:
- Male or female subjects with a diagnosis of idiopathic Parkinson's disease.
- Daily L-dopa dose between 300 and 1200 mg.
- MBRS score >1.
Exclusion Criteria:
- Surgical intervention for Parkinson's disease.
- History of troublesome dyskinesias.
- Any significant AXIS I psychiatric disease.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials